<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00097513</url>
  </required_header>
  <id_info>
    <org_study_id>85-036, Substudy 12</org_study_id>
    <nct_id>NCT00097513</nct_id>
  </id_info>
  <brief_title>National Cooperative Growth Study (NCGS) of Optimal Nutropin AQ and Nutropin Dosing in Pubertal Growth Hormone-Deficient (GHD) Patients</brief_title>
  <official_title>National Cooperative Growth Study (NCGS) of Optimal Nutropin AQ and Nutropin Dosing in Pubertal Growth Hormone-Deficient (GHD) Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This study is a multicenter, open-label, observational, postmarketing surveillance study that
      will collect information on the use of Genentech GH preparations to treat GH-deficient
      subjects with optimal GH dosing during puberty.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <condition>Dwarfism, Pituitary</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Pubertal Growth Hormone Deficiency
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adolescent boys who are GH deficient and Tanner Stage 2 or greater (testes 3 mL or
             greater)

          -  Adolescent girls who are GH deficient and breast Tanner Stage 2 or greater

          -  Current treatment with GH dose of 0.4 to 0.7 mg/kg/wk

          -  Ability to keep follow-up appointments throughout the study

          -  Willingness to remain on therapy until epiphyseal closure is achieved

          -  Prior enrollment in NCGS Core Study 85-036

        Exclusion Criteria:

          -  Treatment with non-Genentech GH preparation

          -  Closed epiphyses

          -  Active neoplasia

          -  Treatment with insulin for diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Lippe, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Genentech Central Contact</name>
      <address>
        <city>South San Francisco</city>
        <state>California</state>
        <zip>94080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2004</study_first_submitted>
  <study_first_submitted_qc>November 24, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2004</study_first_posted>
  <last_update_submitted>November 11, 2010</last_update_submitted>
  <last_update_submitted_qc>November 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Disclosures Group</name_title>
    <organization>Genentech, Inc.</organization>
  </responsible_party>
  <keyword>Pubertal Growth Hormone Deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dwarfism</mesh_term>
    <mesh_term>Dwarfism, Pituitary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

